How does HIV 1 infect a susceptible human cell? ACQUIRED IMMUNODEFICIENC Y SYNDROME (AIDS) was first described in 98 as a group of clinical signs and symptoms caused by the impairment of the immune system, mainly the cellular immune response.1,2 The conditions defining AIDS were recognised by the Centre for Disease Control (CDC), in Atlanta, Georgia (USA), before the identification of the human immunodeficiency viruses (HIVs) as the causa- tive agents for the syndrome. The CDC classification for AIDS, list numerous opportunistic infections and neo- plasms (cancers) which in the presence of HIV infection How does HIV-1 infect a susceptible human cell? Current thinking Ali A. Al-Jabri Department of Microbiology and Immunology, College of Medicine & Health Sciences, Sultan Qaboos University, P.O. Box 35, Al Khod-123, Muscat, Sultanate of Oman. Email: aaljabri@squ.edu.om A B S T R AC T. To insure its survival, the human immunodeficiency virus (HIV), the causative agent of acquired immunodeficiency syn- drome (AIDS), utilises more than one gate to enter a target cell. This strategy makes it more difficult for the immune system to defeat the virus. This has also made it difficult for scientists working in the HIV research to understand how exactly HIV infects a susceptible human cell. Such understanding will no doubt open many gates for scientists to vanquish the virus by designing agents that can block HIV entry into target cells, thus rendering the virus vulnerable to immune destruction. This will also help in understanding the replication of the virus and the pathogenesis of the disease. The present article briefly describes the past and current thinking of how HIV-1 infects a susceptible human cell, and the dilemma scientists are facing when studying the infectivity of this virus and applying current knowledge to design agents that can block HIVs entering target cells. In the context of our own experience with HIV infectivity in vitro, the present article will also address the behaviour of different HIV isolates, both laboratory-adopted and clinical (primary) isolates in culture and the difficulties in performing HIV infectivity testing. Moreover, our experience of peripheral blood mononuclear cells’ (PBMCs) susceptibility to HIVs infection in vitro is discussed. Key words: HIV, AIDS, infection, immune, virus, susceptible cell constitute an AIDS diagnosis.3 In addition, a CD4+ T- cell count below 200 per mm3 in the presence of HIV infection constitutes an AIDS diagnosis. People with AIDS often suffer infections of the lungs, brain, eyes and other organs, and frequently suffer debilitating weight loss, diarrhoea and are vulnerable to a type of cancer known as Kaposi’s sarcoma. Although there is no cure for AIDS at present, multiple drug therapy dramatically improves the quality of life for most people with AIDS.4 The HIVs are well accepted as the causative agents of AIDS.5–8 Formatted in medit HIV review �������� ������� ����� ���� ������ ������� ������ ���)����� (������ �������� ���� ���� ���������� ����� �� ��������:����� ���� ������������ ������� ����� ���� ������ ������� ���)����� (��� �� ���� ����������� ����� �� �� ������ ������ ��� �� ������� ���� ���� ������ ������� ������ ��� ����-� .���� ���� ������ ������� ���� ������� ������� ������� �� ������ �� ����� ������� .�������� ����� ���� ���� �� ����� ������ ������� ���� ������ ����� ���������� �������������� ��� ���� ���� ��� .���� ������ ���� ������ ����� �� ������� ������� �� �� ����� ����� ��� ������ ������� ������ �� ����� ��� �������� ������ ���� �� ������� ���� ���� �������� ������� ��� ���� �� ������� ���������� ���� ����� ����� ������.���� ��� ����� ���� ���� ������� ��� ���� ��� �� ����� ��� ������� ���� ���� ������ ����� ��� ��� �� ��� ������� ������ ����� ���.������������ ���������� ������ ������� ������������� ���� �� ������ ���� ������ �� ������� ���� ����� �������������� ��� ��� �������� �������� � .��� ��� ������������������������ ������� �� ��� ����� �� ������� �� ������ ������ �� ������ ������ ���� ���� �� ������ ������.�� ������ ����� ���� ���� �� �������� ������ ������ ��� ������ ���� ����� �� ������������ �� �� .��� �� ���� ������� ������ ������ �� ����� ���� ������� ���� ������ �� ������ �������� ��������� ����� ����� ��� ������ �� ������ �������. SQU JOURNAL FOR SCIENTIFIC RESEARCH: MEDICAL SCIENCES 2003 VOL 5, NO. –2, 3–44 ©SULTAN QABOOS UNIVERSIT Y R E V I E W 32 AL-JABRI To be able to defeat the HIVs and design the proper prevention tools, basic scientific knowledge on how exactly these viruses infect human susceptible cells is essential. Although the literature is immense on this topic, in this short article I will briefly review our current understanding of how HIVs infect human susceptible cells and the application of this knowledge in designing drugs that can inhibit HIVs entering susceptible human cells. T H E H U M A N I M M U N O D E F I C I E N C Y V I R U S E S ( H I V S ) The HIVs are members of the lentivirus subgroup of the Retroviridae family. They are RNA viruses that pos- ses the enzyme reverse transcriptase (RT). This enzyme allows the virus to reverse-transcribe its own RNA, and the resultant complementary DNA (cDNA) is incorpo- rated into the cellular DNA of the host. Two main types of HIV exist: HIV- and HIV-2, which differ in genomic structure and antigenicity as well as in their latent period as pathogenicity. HIV- was identified, as the causative agent of AIDS, by three different groups in the early eight- ies. These were Montagnier’s at the Pasteur Institute in Paris (France), Gallo’s at the National Institute of Health (NIH) USA, and Levy’s at the University of California San Francisco (UCSF), USA. The HIVs were initially called LAV (lymphadenopathy-associated virus), HTLV- III-human T lymphotropic virus and ARV (AIDS associ- ated retroviruses).5,6,8 In 986 a second virus (HIV-2) was identified,9 and the original was renamed HIV- to dis- tinguish them. The diameter of the HIV virion is approx- imately 00 nm and electron microscopy studies have revealed a characteristic cylindrical core in HIV parti- cles surrounded by an outer envelope [Figure ]. HIV- The inner core of HIV- consists of p24 protein (cap- sid). Inside this capsid are two copies of single stranded genomic RNA and the enzymes required for the initial stages of HIV- replication. These include the reverse transcriptase (p5/66), integrase (p32) and protease (p22). The inner core also contains p7 nucleic acid bind- ing protein and p9 gag binding protein. The inner core is surrounded by a p7 myristylated gag matrix pro- tein, thought to be essential for maintaining the struc- ture of the virus or stabilising the exterior and interior components of the virion. The p7 protein is bounded by a lipid bilayer membrane (the outer envelope). This outer envelope contains spikes made up of gp20 and gp4. The gp20 contains the receptor binding region involved in infectivity as well as in syncytia formation (a major cytopathic effect of HIVs in vitro) and the gp4 is a transmembrane segment which is important for virus fusion.10,11,12 The HIV- lipid bilayer also contains various host cell proteins including HLA class I and II that are acquired during virus budding (Figure ). HIV-2 Although the general structure of HIV-2 is similar to that of HIV-, differences within the genomic structure exist and genetic regulation of HIV-2 also differs from that of HIV-.9,11,12 This article will be referring mainly to HIV-. Figure 1 b. Simple diagram illustrating the main components of the basic structure of HIV-1. Figure 1. Electron micrograph of HIV-1 and HIV-2 (MN and ROD). HIV-1 (MN) virions are shown budding (arrow). HIV-2 (ROD) virions are shown in (b) (above). Magnification is 100,000 x. Scale bar =100nm. This electron microscopy was kindly performed by Dr. Robert Dourmashkin. 33H O W D O E S H I V I N F E C T H U M A N C E L L ? SUBT YPES OF HIVS Now it is well established that there exist many sub- types of HIVs. The HIV--M (main) group subtypes are phylogenetically associated groups or clades of HIV- sequences, and are labelled A, A2, B, C, D, F, F2, G, H, J and K. The sequences within any one subtype or sub- subtype are more similar to each other than to sequences from other subtypes throughout their genomes. “O” is the “outlier” group, and group N is also a very distinctive form of the virus that is Non-M, Non-O (also sometimes referred to as the “new” group). For HIV-2, there exist A, B, C, F or G clades (formerly known as “subtypes”, now referred to as “groups”). The nomenclature of HIVs is becoming even more difficult with the introduction of Recombinants and Circulating Recombinant Forms as a result of inter-subtype recombinant genomes of differ- ent HIV clades. The existence of many subtypes of HIVs make it extremely difficult for vaccinologists to design the proper vaccine against HIVs, since certain subtypes circulate more than others in different populations. For example subtype B of HIV- is more common in western countries than subtypes C and D. HIVs are also named according to how they behave in culture producing cytopathic effects: sysncytium inducing isolates (SI) and none syncytium inducing isolates (NSI). Moreover, HIVs can also be called macrophage tropic (M-trpic), T cell line tropic (T-tropic), or dual tropic, when they are able to infect macrophages, T cells and both macrophage and T cells, respectively. CELL TROPISM IN HIVS HIVs are termed retroviruses because they “reverse” the normal flow of the genetic information, i.e. RNA is reverse-transcribed to DNA. Until the mid nineties, it was considered that HIV- enters its host cell through the attachment of the envelope glycoproteins (gp20) to the CD4 molecules (receptors), found on T-helper cells, monocytes and macrophages.10 HIVs can also enter cells by other means, for example, through the Fc receptors of antibodies and complement receptors CR2 and CR3.11,12 After gp20 binds to a CD4 molecule, a conformational change is induced in the gp20, leading to its dissocia- tion from the viral membrane. This results in the expo- sure of the amino terminal hydrophobic domain of the gp4which initiates the fusion process. The HIV, then, enters its host cell via membrane fusion, a pH independ- ent process.13,14,15 The virus sheds its protein coat after entry into the cell, exposing the RNA core [Figure 2]. The enzyme reverse transcriptase is activated and tran- scribes the RNA into complementary DNA. The RNA is removed by ribonuclease H activity, and a second DNA strand is synthesised complementary to the first. This double-stranded DNA is integrated into the genome of the host cell by the viral integrase, with the potential for viral production at any time. The integrated DNA is termed a provirus and this provirus DNA can be tran- scribed into mRNAs, which direct the synthesis of viral proteins.12 V3 LOOP OF THE GLYCOPROTEIN (GP) 20 Before HIV is able to gain entry into a target susceptible cell, the third hypervariable region (V3) loop of the sur- face glycoprotein gp20 molecule has been implicated as an important factor for cell tropism and for cell fusion. The determinants of HIV tropism can be mapped to the viral envelope gene,16–22 thus indicating that tropism is restricted at the level of virus entry. A significant find- ing was that a major determinant of HIV- tropism is the V3 region of the surface gp20.16–18 The HIV- envelope gene is approximately 2.5 Kb in length and gp20 has a .6 Kb nucleotide sequence. The gp20 is divided into six constant (C–C6) and five hyper-variable regions (V– V5).19,20 Studies have already shown that mutations (sub- stitutions) in the V3 loop are essential in cellular tropism and in the antigenicity of gp20.21 The V3 loop, known as the principal neutralising domain (PND), is considered to be the major immunodominant region of the gp20 for both HIV-22,23 and HIV-2.24 This domain induces neutralising antibodies and is the target for cytotoxic T lymphocyte killing.25 Neutralising antibodies are able to block infection in vitro by blocking fusion of the virus.23 The acquisition of the syncytium inducing (SI) pheno- type is linked to substitutions of acidic or neutral amino acids by more basic amino acids in the V3 loop.26 The V3 loop does not seem to play an important role in CD4 binding, since V3 specific antibodies do not affect the attachment of gp20 to CD4. However, the V3 loop is essential for virus infection, since V3 loop spe- cific antibodies can block fusion and entry of HIV to sus- ceptible cells.27 The V3 loop typically begins at amino acids number 300 and consists of between 33 to 35 amino acids bounded by disulphide linkage. At the tip of the loop is the sequence Gly-Pro-Gly-Arg (GPGR), known to be the most conserved region among HIV- clade B isolates.28 While the GPGR crown of the V3 loop of HIV- is con- served within all clade B isolates, the equivalent in HIV- 2, FSHQ, seem to be conserved among HIV-2 isolates. A single amino acid substitution in the HIV- V3 loop has already been shown to change an isolate from non syncytium inducing (NSI) to a syncytium inducing (SI) phenotype.21 34 CHEMOKINES ARE THE CO-RECEPTORS FOR HIVS ENTRY Nowadays it is well understood that the CD4 molecule alone is not sufficient to render a target cell permis- sive for fusion with virions (see below). Although the main receptors for HIV- entry into target cells is the CD4 molecules, the seven trans-membrane spanning G protein chemokine receptor family are now accepted as important co-receptors for virus entry.14,29,30,31,32 Many chemokine co-receptors were identified, including CCR-5 and fusin, and known to act as sec- ondary receptors for virus entry.33,34,35 Fusin is expressed on a wide range of human cell lines; those which do not express fusin are not infected by T cell-tropic HIV- . Importantly, cells expressing both CD4 and fusin remained refractory to macrophage (M)-tropic HIV envelope mediated fusion, consistent with the earlier prediction that fusion cofactors for T- and M-tropic HIV- strains would be distinct moieties. Furthermore, a CXC chemokine (SDF-), has subsequently been iden- tified as a ligand which both binds fusin and specifically blocks infection by T-tropic but not M-tropic HIV- strains.36,37 Based on the identification of its chemokine ligand, fusin was renamed CXCR-4. The discovery that CXCR-4—whose closest known homologous is the IL-8 receptor (CXCR-2)—constitutes a functional co-receptor for T-tropic HIV- strains, added significance to the earlier finding that the C-C chemok- ines MIP--alpha, MIP--beta and RANTES are able to block infection of CD4+ human T-cells by M-tropic but not T-tropic HIV-.38 Thus, since certain chemokines are known to bind several of the seven transmembrane receptors, it became likely that the discovery of a chem- okine receptor that is recognised by all three of these chemokines would also result in the identification of an M-tropic HIV- specific co-receptor. ROLE OF CHEMOKINE CO-RECEPTORS The interaction of HIVs with a target cell is initially with CD4, thereby inducing a conformational change in gp20, which facilitates subsequent binding of envelope to the co-receptor.33,34 It is likely that the virus binding site or sites on the co-receptor involve multiple extra- cellular domains, and that within each of these domains multiple amino acids contribute to co-receptor function. While this complexity has largely frustrated attempts to define precise virus binding sites, studies of chimeric and mutant co-receptors have, to some extent, illuminated our understanding of how HIV interacts with co-recep- tors and suggested that several, functionally redundant, interactions between co-receptor and virus envelope are likely to occur. This has implications for the feasibility of using co-receptor targeted inhibitors of virus entry as therapies.39 �������������������������������� Figure 2. The life cycle of HIVs AL-JABRI Coursey of Ms. Lesley Mclain, Warwick University 35 CO-RECEPTOR RECOGNITION Culturing virus in the laboratory imposes different selective pressures on viral populations that are likely to impact on the nature of their interaction with receptors. In addition, there are examples of very minor envelope sequence changes drastically influencing co-receptor recognition,39,40,41,42 thus different results are likely to be obtained with cloned versus uncloned forms of the same virus isolate. The relative expression levels of co-recep- tors on transfected cells, as compared to the natural tar- gets of virus infection, remain largely unexplored and clearly affect the efficiency of infection. It was noted that over-expression of some chemokine receptors render cells permissive for viral envelope induced cell fusion, while cells expressing lower levels of the same co-recep- tor remain resistant to infection by cell-free virus.43 It is clear that there is considerable plasticity in co-recep- tor usage, both in terms of the viruses ability to use one or more of a number of “optional” co-receptors and the ability of strains to use a given co-receptor in different ways.40,42 CELL LINES AND IN-VITRO INFEC TION WITH HIVS Our experience with T cell lines, namely, C866, H9 and CEM which we tested and compared in relation to infec- tivity by four different HIVs, showed variation in both the time at which the HIV cytopathic effects (syncy- tia formation) were first observed, and the number of syncytia formed.44,45,46 Moreover, the replication capac- ity of each virus in each of the cell lines differed widely. The CEM cell line was shown to be the least infectable, whereas C866 was very susceptible to infection by the three laboratory-adopted HIVs, MN, CBL-20, ROD and one fresh clinical HIV- isolate (H995). Although other factors may be involved in the susceptibility of the C866 cells to HIV infection, the characteristic tendency of these cells to clump in culture may facilitate the infectiv- ity process. The C866 cell line was shown to be the most susceptible to infection by the laboratory adopted HIV strains MN, ROD and CBL-20 with high rates of repli- cation. The C866 cells showed large syncytia (balloon shaped) early in culture usually by day two post infec- tion compared with other cell lines whilst the number of syncytia formed depended directly on the concentration of the virus [Figure 3]. The H9 cell line was also infectable by all four men- tioned HIVs. However, it was not as susceptible as C866 in terms of the number of syncytia observed and the lev- els of viral replication. The CEM cell line was the least infectable showing very few syncytia at the highest concentration of the MN strain (TCID50 of approxi- mately 05/ml). All these experiments, performed on cell lines, were reproducible confirming that the syncytium inducing ability of each HIV strain was a stable prop- erty for that particular virus. This is important in studies when infectivity results are compared between different experiments. Due to the differences in the behaviour of these cell lines to infection by each virus, and because these cell lines differ in their human leukocyte antigens (HLA) type, it is possible that HLA may have a role to play in HIV infectivity. The HLA-A allele, expressed on the surface of the C866 cells, is believed to be associated with progression of AIDS from in vivo studies. In con- trast, the CEM cell line which expresses none (or very low levels) of HLA class II DR antigens when activated12 showed very small syncytia which took longer to develop compared to the other cell lines (C866 and H9). Thus, Figure 3b. Cytopathic effects of HIV-1 infection in vitro, using H9 cells (syncytia formation) Figure 3a. Normal healthy H9 cells. H O W D O E S H I V I N F E C T H U M A N C E L L ? Coursey of Ms. Lesley Mclain, Warwick University 36 these results on cell lines support the possibility of a role for the HLA in the HIV infectivity process. Furthermore, we have shown that HLA do correlate, although weakly, with in vitro high or low HIV virus replication.44,45,46 Our in vitro results showed clearly that certain HLA specif- icities were significantly correlated in vitro with infec- tivity by both HIV-s and HIV-2s and that each isolate had its own correlation with HIV infection.44,45 This may partly explain the differences in the in vivo results on the association of HLA with certain features of AIDS and the difficulty in confirming such correlation. However, more studies in vitro and in vivo on a large scale and on groups who are at high risk or low risk need to be addressed with the identification of the HIV isolate that is predominant in each individual patient. These stud- ies will characterise better those HLA specificities that are important for infectivity by HIV- and HIV-2. The existence of a significant HLA association with all the known HIV- and all HIV-2 isolates infecting human populations may lead to the identification of important immunodominant epitopes that can be useful in vaccine development against the different clades (subtypes) of HIVs. There is a possibility that HLA are not the actual genes responsible for susceptibility or resistance to HIV infection, rather other, as yet unidentified genes closely linked to HLA, or masked by the HLA, could be the real genes determining susceptibility or resistance to HIV. This can be revealed only by intensive future research work and by better knowledge and understanding of the genes that are linked to the HLA molecules.45 While many immortalised human T-cell lines can be infected by laboratory adapted HIV- and HIV-2 strains, other CD4 positive cell lines are sometimes selectively permissive only for specific virus types.32 From our laboratory experience, when dealing with HIV- and 2, laboratory-adopted strains compared to fresh clini- cal (primary) isolates, heterogeneity in tropism is evi- dent within a given virus type. For HIV-, virtually all strains replicate efficiently in CD4+ peripheral blood mononuclear cells (PBMCs). However, many freshly isolated or primary strains are also able to propagate efficiently in primary macrophages but not in immor- talised T-cell lines and are thus termed M-tropic. Conversely, other strains, particularly those which have been adapted to growth in immortalised T-cell lines (T- tropic), generally do not efficiently infect primary mac- rophages.47,48,49,50 Other groups of HIV isolates (termed dual-tropic) are able to replicate well in both T-cell lines and primary macrophages in addition to PBMCs.51,52,53 Dual-tropic and T-tropic strains induce cell fusion in primary and immortalised T-cells and are also referred to as syncytium-inducing (SI). The V3 loop is an excel- lent candidate for being a component of a co-receptor binding site. The V3 loop is not the sole determinant of co-receptor recognition. In some cases, alternative trop- isms can be mapped to non-V3 sequences.20,21,22 HIVS AFFEC T ON RECEPTOR USAGE To speculate as to why HIVs have evolved plastic- ity in their interactions with co-receptors is impor- tant. The ability to use multiple functionally redundant contacts with co-receptors could conceivably facilitate immunological escape.54-60 Thus, in the face of a neu- tralising antibody response (which, in significant part, is directed against V3 sequences,61-65 a major modulator of co-receptor interaction), the selection of variants with altered envelope sequences would be permitted without compromising the ability of the virus to use a given co- receptor. 39 Furthermore, changes in envelope sequence, that enable the virus to use additional co-receptors while retaining the ability to interact with CCR-5, could be tol- erated. It appears that dual-tropic strains that use both CCR-5 and CXCR-4 are less tolerant of perturbations in CCR-5 sequence than are M-tropic strains,66,67 sug- gesting that acquisition of the ability to utilise CXCR- 4 might involve the sacrifice of a degree of functional redundancy and/or affinity in the envelope/CCR-5 inter- action.39 During the early, asymptomatic phase of HIV- infec- tion M-tropic strains predominate. It is quite possible that this is the simple consequence of a ‘founder effect’: It is likely that the major route of transmission of HIV- is via infection using CCR-5 as a co-receptor, given the observation that CCR5 delta32 homozygous individuals are much less likely to be HIV infected than those with other genotypes.39 However, why do strains that also use CXCR-4 tend to arise only late in the course of infection, when in many cases they retain the ability to use CCR-5? While it has often been noted that SI viruses are associ- ated with poor prognosis it is important to emphasise that the occurrence of SI viruses that can use CXCR-4 (and usually CCR-5) is only a correlate of disease pro- gression.64,65 Although it is possible that a presumptive expansion in tropism might accelerate the course of HIV- disease, particularly since CXCR-4 is expressed on the naive T-cells subset from which CCR-5 is largely absent,68 it is equally possible that CXCR-4 utilising viruses arise as a consequence of, rather than being the cause of immunosuppression. Viruses isolated from a laboratory worker who was accidentally infected with the exclusively T-tropic, IIIB strain became M-tropic with time.69 It is known that the selective pressures on AL-JABRI 37 co-receptor utilisation are different in vivo as opposed to in vitro. At least two scenarios could be envisaged that provide CCR-5 utilising viruses with a selective advan- tage: Firstly, it is conceivable that major selective influ- ences are the result of envelope directed neutralising immune responses, which could impose a restriction on the nature of co-receptor utilisation. Indeed, neu- tralisation phenotype and viral tropism (and therefore, presumably, co-receptor selection) are not independ- ent properties of the viral envelope.70 A general obser- vation is that primary HIV- isolates (which tend to use CCR-5 but not CXCR-4) are somewhat more resistant to neutralisation by naturally occurring HIV- antibodies than are laboratory adapted strains.71 Thus, it is possible that immunological constraints are placed on envelope sequence and conformation that could negatively influ- ence the ability of the virus to use CXCR-4 as a co-recep- tor.39 Therefore, the occurrence of CXCR-4 utilising variants late in the course of disease might be a reflec- tion of compromised ability of the infected individuals to mount immune responses to new variants capable of utilising CXCR-4 that would have been readily neu- tralised earlier during the infection. Conversely, a selec- tive advantage for HIVs that use CCR-5 may be immune response-independence. An equally plausible hypoth- esis is that CXCR-4 utilising strains become prevalent only late in disease as a result of the selective depletion of CD4+ memory T-cells (the subset that preferentially expresses CCR-5). These are replaced at a high rate by naive counterparts which (at least in uninfected individ- uals), express higher levels of CXCR-4 than of CCR-5,68 thus providing T- or dual-tropic strains with a selective advantage. Regardless of the selective pressures on co- receptor usage, the occurrence of SI viruses in only about 50% of patients with advanced disease indicates that the ability of the virus to use CXCR-4 is by no means neces- sary for the onset of immune suppression.72,73,74,75 GLYCOPROTEIN-20 CO-RECEPTOR INTER AC TIONS It is known that gp20 CD4 interaction induces confor- mational changes in envelope, which expose previously concealed epitopes.76 These changes are not sufficient to induce membrane fusion; rather they are likely to facili- tate co-receptor binding. Presumably co-receptor bind- ing results in additional conformational modification, ultimately resulting in exposure of the gp4 N-termi- nal fusion peptide. The physiological function of seven trans-membrane receptors is to transduce signals via coupling to G-proteins. In several cases where post sig- nalling events have been studied (using predominantly the beta-2-adrenergic receptor as a prototype) signalling is rapidly followed by receptor phosphorylation (medi- ated by specific G-protein coupled receptor kinases). Phosphorylation results in desensitisation of the recep- tor and recognition by arrestins that are necessary for the subsequent internalisation and recycling of the phosphorylated receptor.77 Other scientists have inves- tigated whether any of these processes are coupled to the function of CCR-5 as an HIV- co-receptor.39,78,79,80 It may be possible that gp20/CCR-5 interaction might result in signalling, even though this may not be a neces- sary event for HIV- entry to occur. Clearly much remains to be learned about the nature of viral envelope–co-receptor interactions. The func- tional sequences of the first wave of co-receptors are only partially characterised, and more data relating to those of the newly identified co-receptors is awaited. Moreover, the extent to which non-V3 sequences influ- ence recognition of the expanding array of co-receptors is yet to be determined. It is also unclear to what extent co-receptors other that CCR-5 and CXCR-4 are truly uti- lised in vivo. For example, do viruses present in CCR-5 delta32 homozygotes utilise exclusively CXCR-4? Is the frequency of viruses using alternative receptors more frequent in individuals who express low levels of CCR-5? Virtually nothing is known about how the expression of co-receptor genes is regulated, and whether or not this might be a potential target for therapeutic intervention. Given the many unanswered questions, there can be no doubt that the already substantial number of publica- tions on the subject of HIVs co-receptors will continue to grow for the foreseeable future.39 INHIBITION OF HIVS ENTRY The entry of HIVs is currently understood to be essentially a three-step process consisting of attach- ment, chemokine co-receptor interaction, and fusion. Therefore, specific areas of interest to inhibit HIVs entry include blocking gp20 binding to CD4 cell receptors (attachment inhibitors), blocking the binding sites of co-receptors such as CCR5 and CXCR4 (chemokine co- receptor inhibitors), and disrupting the fusion process (fusion inhibitors). The fusion inhibitor, enfuvirtide (formerly called T- 20), a 36-amino acid peptide being developed jointly by Trimeris and Roche, is in the most advanced stage of clinical development. HIV fusion with CD4 cells is a complex process, and not very well understood, and involves a conformational change in the HIV envelope gp20/gp4, leading to an interaction between gp4 that lead to intimate proximity between the HIV envelope H O W D O E S H I V I N F E C T H U M A N C E L L ? 38 and the cell membrane, allowing fusion to occur. Enfuvirtide is active against both CCR-5- and CXCR4- using viruses and are synergistic with CCR5 and CXCR4 antagonists.60 Many companies including Glaxo SmithKline are now investigating inhibitors of CCR5 and CXCR4. The lead Pfizer compound, UK-427, 857, is a non-competi- tive inhibitor of CCR5 that has an IC50 of 0.7 nmol in PBMCs, making it a more potent inhibitor of the co- receptor than RANTES, one of CCR-5’s natural ligands. The agent is active across a range of HIV- subtypes. Another candidate, the Takeda compound, TAK-220, has a mean IC50 of 4.37–0.5 nmol in PBMCs with no toxic effects observed in cell cultures at concentrations up to 00 nmol. The Ono compound, known as AK602, is active against HIV- with an IC50 of 0.2–0.6 nmol, and appears to bind non-competitively to the receptor.60 The identification of co-receptors that mediate HIVs entry might well have major significance for attempts to treat HIV infection. The chemokines themselves are inhibitors of HIV entry,36,37,38 and modified forms of RANTES, which bind CCR-5 yet fail to induce signal transduction, have similar properties.54,55 Beta chemok- ine homologues encoded by Kaposi’s sarcoma associated herpes virus have also been shown to block HIV- infec- tion.56, 57 The lack of an overt phenotype associated with CCR-5 delta32, even among homozygotes,58,59 suggests that antagonists targeted specifically to this co-recep- tor should be relatively free of undesirable side effects. It might be possible to develop small molecule inhibi- tors that block viral interactions with CXCR-4 without compromising SDF- signal transduction, peptide and bicyclam compounds targeted to CXCR-4 that pre- vent T-tropic HIV infection have been described.61, 62, 63 However, all of these compounds also block signal- ling through CXCR-4. A potentially serious obstacle in the development of co-receptor targeted therapeutics is the plasticity of envelope co-receptor interactions.39 It is quite conceivable that co-receptor targeted compounds would simply select for strains that use an alternative co-receptor, or different regions of the same co-receptor. Furthermore, since AIDS has been documented in CCR- 5 delta32 homozygotes, it is unlikely that even total abla- tion of the CCR-5 entry pathway will achieve much more than retardation of disease progression, once infection has been established. There is a possibility that CCR-5 targeted therapy might accelerate the course of disease by selection of viral strains that use alternative co-recep- tors (most notably CXCR-4, but also including CCR-2b and CCR-3) whose occurrence is associated with disease progression.64 It is possible that combinations of agents that ablate the co-receptor function of both CCR-5 and CXCR-4 would have a significant impact on the ability of HIV to propagate in vivo. CY TOPATHIC EFFEC TS PRODUCED BY IN VITRO INFEC TION WITH HIVS The molecular mechanism by which HIV induces cytopathology in susceptible cells is not well under- stood. In vitro HIV infected cells formed multinucleated giant cells (syncytia) [Figure 3] that can produce large amounts of virus before they die, within a period of a few days, normally within 48 hours.81 Syncytia forma- tion in culture results from fusion of infected cells with uninfected CD4+ cells82 and involves the CD4 molecule and HIV gp20 and gp4 proteins.83,84 Although the pre- cise mechanism is still not known, syncytia formation is linked to the V3 loop of gp20 envelope region.85,86 Thus, the differences in the amino acids sequences of the V3 loop determine SI versus NSI isolates and whether an HIV isolate will induce syncytia formation or not. T cell tropic (SI) viruses generally have a basic amino acid at one or more of the positions , 24, 25 and 32 of the V3 loop, whereas macrophage tropic (NSI) viruses have either an acidic amino acid or alanine at position 25. Generally syncytia formation is the most common event preceding cell death in vitro. There is some evi- dence that syncytia can occur in vivo and syncytia have been observed in the lymph nodes of homosexual men with lymphadenopathy, in lymph nodes and lungs of children with AIDS and in brain tissues of some adult patients who died with AIDS and is therefore possibly important in the pathogenesis of AIDS.87 Although syncytia formation may be an indirect indi- cation of how virulent an HIV isolate is, syncytia forma- tion itself is a direct effect of viral replication. Since the replication of HIVs depends on cellular activation and because HLA can cause activation of T cells through a mimicry mechanism,44,45,46 syncytia formation may indi- rectly depend on the HLA type of the PBMCs, which will determine the degree of cellular activation and hence the degree of viral replication. As explained earlier, antigenic variation of the enve- lope protein of HIV is believed to be essential for the virus to escape specific humoral and cell-mediated immune responses that otherwise would suppress the replication of the virus. Moreover genetic variation can also lead to the emergence of more virulent syncytium-inducing (SI) isolates of HIV that may accelerate the progression of dis- ease in infected individuals.88 Millions of genetic variants of HIVs can exist within one host and this diversity may be essential for the survival of the virus within its host. AL-JABRI 39 SUSCEPTIBILIT Y OF PBMCS TO INFEC TION WITH HIVS PBMCs include monocytes, lymphocytes and circulat- ing dendritic cells. Monocytes can be infected by HIVs, and the susceptibility to infection can be observed at all stages of maturation.89 However, the kinetics of virus replication depends on the stage of cellular differentia- tion at the time of virus infection. CD4 (T helper) cells, the main target for HIVs, express the CD4 receptors and their destruction is associated with the deterioration of the immune system. T-lymphocytes do not support a productive infection with HIVs in vitro, unless they are first stimulated with agents such as mitogens or anti- gens.90 Activated T lymphocytes are easier to infect than non-activated ones. Our experience of the differences of HIV infection observed among PBMCs from different individuals was not due to the differences in cell types (T cells, B cells and monocytes). Yamada et al,91 had found that differ- ences between cultures still exist even if monocytes were removed and the remaining cells were only T cells. Williams and Cloyd92 also reported differences between CD4+ cell clones to infection by HIV indicating that the differences observed between different PBMCs to infec- tion were most likely due to cellular factors. Moreover, these differences were not related to differences in CD4 antigen positive lymphocytes or to differences in cell growth.91 In addition, our finding that cells from some individ- uals produced more virus than others may indicate that this was due to the differences in lymphocytes proliferat- ing in culture.44,45,46 However, considering that the con- centration of PHA (and also IL2) used for lymphocyte stimulation and activation was the same in all cultures used in our tests, and that the cell concentration was also the same, then cell proliferation due to the presence of PHA may not be the answer for the differences observed among individual PBMCs. Therefore, factors that can cause cellular activation (which are different between different batches of PBMCs—e.g. HLA system)44,45,46 may provide an explanation for the differences in viral replication. Knowing the factors that determine suscep- tibility of PBMCs of an individual may also be important for in vitro initial HIV drug screening using PBMCs.44,46 RESISTANCE TO HIV INFEC TION The poorly understood phenomenon associated with the HIV- epidemic is the existence of individuals who have been repeatedly exposed to the virus but remain uninfected. It has been suggested that HIV- resistant individuals may have a non functioning co-receptor (such as CCR-5) preventing the virus from entering cells.59,93 The CCR-5 receptor was demonstrated as one of the main co-receptors for NSI (macrophage tropic) strains of HIV-.34 Samson et al.,59 reported that a 32 bp deletion within the coding region for the CCR-5 generating a non-functional receptor that did not sup- port infection by NSI strains of HIV-. Moreover, white blood cells from individuals homozygous for the mutant CCR-5 were found to be highly resistant to infection by NSI viruses.59,93 Population studies indicate that the homozygous defect is found in only % of Caucasians of western European ancestry whereas the heterozygous defect is present in approximately 20% of this popula- tion.58 These results indicate that variants of the CCR-5 receptor could be responsible for the relative resistance to HIV- infection exhibited by some individuals and also for the variability of the course of the disease in infected patients. In vitro results reported by many studies and our own44–46,91,58,94 showed no single PBMC was completely resistant to infection by different HIVs. The possibil- ity that certain individuals are completely resistant to either, HIV-, HIV-2, or both, still exists. Studies of larger groups may reveal whether certain individuals are completely resistant to HIV infection. In some of these cases, a substantial in vitro infec- tion resistance (specifically to CCR-5 utilising, M-tropic strains) of PBMCs and macrophages is evident.95,96 In addition, it is well known that there are large variations in the rate of progress of the disease among individu- als who do become infected. Analysis of CCR-5 genes has revealed the existence of a defective CCR-5 allele that may contribute to each of these observations.58,59,97 Moreover, individuals who are heterozygous for the two major CCR-5 alleles do not manifest a high degree of infection resistance.59, 97 However, once infected, the progression of disease in heterozygotes appears to be somewhat retarded. This phenotype is associated with a measurably reduced virus load post seroconversion, and a decrease in frequency of symptomatic primary infec- tion.98 Taken together, these observations strongly imply that the major route of HIV transmission both between individuals and between cells within an individual (at least during the early stages of infection) is mediated by the CCR-5 co-receptor. Other receptors such as CCR-3 is only expressed in a restricted sub-population of T-cells99 and is, therefore, unlikely to play a major role in HIV infection of these cells. However, it is relatively abundant on microglial cells, the major targets of HIV- in the brain.100 Eotaxin, the physiological ligand for CCR-3, and a CCR-3 reactive H O W D O E S H I V I N F E C T H U M A N C E L L ? 40 monoclonal antibody have both been reported to possess infection inhibiting properties in primary brain cultures. M-tropic strains that are unable to use CCR-3 can also infect brain cultures, suggesting that both CCR-3 and CCR-5 play a role in infection of these cells. An interest- ing, but as yet unexplained, observation is the associa- tion of a CCR-2b polymorphism with retarded disease progression.101 This is unexpected given that the great majority of HIV- strains are not able to use CCR-2b as a co-receptor. The mutant CCR-2b allele, which encodes a receptor with a single valine to isoleucine change, is invariably associated with an intact CCR-5 allele. Since the two genes are very closely linked, it is quite likely that the mutant CCR-2b gene is associated with some, as yet unidentified, defect in CCR-5 expression, although this has not yet been thoroughly investigated. The wide variation of CCR-5 expression levels among individuals homozygous for intact reading frames has been docu- mented, as has a measurably lower expression level in CCR-5 delta32 heterozygotes.102 It might well be that co- receptor expression levels contribute to the very large variation in rates of disease progression, particularly since the amount of CCR-5 expressed on PBMCs from different donors correlates with their ability to support the replication of M-tropic strains in vitro.102 C O N C L U S I O N This review has briefly described how HIVs use differ- ent molecules, including CD4 receptors and chemok- ine co-receptors, to gain entry into a human susceptible cell causing infection. Knowing exactly how HIVs infect peripheral blood mononuclear cells, and the factors that control the susceptibility or resistance of these cells to infection, is of importance for the understanding of the HIVs’ infectivity process. The chemokines are believed to be the most important molecules so far discovered which act as co-receptors for HIV entry. I believe that in the near future we will be seeing more details on the already discovered chemokine co-receptors, and more new co-receptors being discovered. This should aid in designing more potent weapons against the HIVs. R E F E R E N C E S . Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med, 98, 305, 425–43. 2. Masur H, Michelis MA, Greene JB, Onorata I, Vande Stouwe RA, Holzman RS, et al. An outbreak of community- acquired Pneumocystis carinii pneumonia. N Engl J Med, 98 305, 43–438. 3. Centers for Disease Control and Prevention. Revised clas- sification system for HIV infection and expanded surveillance of definition for AIDS among adolescents and adults. MMWR, 993, 4, 7. 4. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guide- lines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med, 2002, 37, 38–433. 5. Barre-Sinoussi F, Chermann JC, Rey R, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic ret- rovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science, 983, 220, 868–87. 6. Popovic M, Sarngadharan MG, Read E, Gallo RC. Detec- tion, isolation, and continuous production of cytopathic ret- roviruses (HTLV-III) from patients with AIDS and pre AIDS. Science, 984, 244, 497–500. 7. Sarngadharan MG, Popovic M, Bruch L, Schupbach J, Gallo RC. Antibodies reactive with Human T lymphotropic retrovi- ruses (HTLV-III) in the serum of patients with AIDS. Science, 984, 224, 506–508. 8. Levy JA, Hoffman AD, Kramer SM, Landis JA, Shimabukuro JM, Shiro LS. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science, 984, 225, 840–842. 9. Clavel F, Guetard D, Brun-Vezinet F, Chamaret S, Rey MA, Santos-Ferreira MO, et al., Isolation of a new human retrovi- rus from West African patients with AIDS. Science, 986, 233, 343–346. 0. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature, 984, 32, 763–767. . Cullen BR. Human immunodeficiency virus as a prototypic retrovirus. J Virol, 99, 65, 053–056. 2. Levy JA. Pathogenesis of HIV infection. Microbiol Rev, 993, 57, 83–289. 3. Stein BS, Gowda SD, Lifson JD, Penhallow RC, Bensch KG, Engleman EG. pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane. Cell, 987, 49, 659–668. 4. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV- coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol, 999, 7, 657–700. 5. Murakami T, Yamamoto N. Roles of chemokines and chem- okine receptors in HIV- infection. Int J Hematol 2000, 72, 42–47. 6. Hwang SS, Boyle TJ, Lyerly HK, Cullen BR. Identification of the envelope V3 loop as the primary determinant of cell tro- pism in HIV-. Science, 99, 253, 7–74. 7. Shioda T, Levy JA, Cheng-Mayer C. Macrophage and T cell- line tropisms of HIV- are determined by specific regions of the envelope gp20 gene. Nature, 99, 349, 67–69. 8. O’Brien WA, Koyanagi Y, Namazie A, Zhao J-Q, Diagne A, Idler K, et al. HIV- tropism for mononuclear phagocytes can be determined by regions of gp20 outside the CD4-binding domain. Nature, 990, 348, 69–73. 9. Willey RL, Rutledge RA, Dias S, Folks T, Theodore T, Buckler CE, et al. Identification of conserved and divergent AL-JABRI 4 domains within the envelope gene of the acquired immunode- ficiency syndrome retrovirus. Proc Natl Acad Sci USA, 986, 83, 5038–5042. 20. Simmonds P, Balfe P, Peutherer JF, Ludlam CA, Bishop JO, Brown AJL. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J Virol, 990, 64, 864–872. 2. Willey RL, Theodore TS, Martin MA. Amino acid substitu- tions in the human immunodeficiency virus type  gp20 V3 loop that change viral tropism also alter physical and func- tional properties of the virion envelope. J Virol, 994, 68, 4409–449. 22. Goudsmit J, Boucher CA, Meloen RH, Epstein LG, Smit L, van der Hoek L, et al. Human antibody response to a strain- specific HIV- gp20 epitope associated with cell fusion inhi- bition. AIDS, 988, 2, 57–64. 23. Kenealy WR, Matthews TJ, Ganfield MC, Langolis AJ, Wase- lefsky DM, Petteway RJ. Antibodies from human immunode- ficiency virus-infected individuals bind to a short amino acid sequence that elicits neutralising antibodies in animals. AIDS Res Hum Retroviruses, 989, 5, 73–82. 24. de Wolf F, Meloen RH, Bakker M, Barin F, Goudsmit J. Characterisation of human antibody-binding sites on the external envelope of human immunodeficiency virus type 2. J Gen Virol, 99, 72, 26–267. 25. Takahashi H, Merli S, Putney SD, Houghten R, Moss B, Ger- main RN, et al. A single amino acid interchange yields recip- rocal CTL specificities for HIV- gp60. Science, 989, 246, 8–2. 26. Fouchier RAM, Groenink M, Koostra NA, Tersmette M, Huisman G, Miedema F, et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type  gp20 molecule. J Virol, 992, 66, 383–387. 27. Ivanoff LA, Dubay JW, Morris JF, Roberts SJ, Gutshall L, Sternberg EJ et al. V3 loop region of the HIV- gp20 enve- lope protein is essential for virus infectivity. Virology, 992, 87, 423–432. 28. Foley B, Korber B. Global variation in the HIV- V3 region. In: Human Retroviruses and AIDS (Eds) Myers G, Korber B, Hahn BH, Jeang K-T, Mellors JW, McCutchan FE, Henderson LE, Pavlakis GN. Los Alamos, National Laboratory, Los Alamos, New Mexico, USA 995, pp III 77–08. 29. Agrawal L, Vanhom-Ali Z, Alkhatib G. Multiple determi- nants are involved in HIV coreceptor use as demonstrated by CCR4/CCL22 interaction in peripheral blood mononuclear cells (PBMCs). J Leukoc Biol, 2002, 72, 063–074. 30. Planelles V, Li Q-X, Chen ISY. The biological and molecular basis for cell tropism in HIV. In Cullen BR (ed.), Human Retro- viruses Oxford University Press, Oxford, UK, 993, 7-48. 3. James W, Weiss RA, Simon JH. The receptor for HIV: Dissec- tion of CD4 and studies on putative accessory factors. Curr Top Microbiol Immunol, 996, 205, 37–58. 32. Clapham PR, Blanc D, Weiss RA. Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types  and 2 and by simian immuno- deficiency virus. Virology, 99, 8, 703–75. 33. Feng Y, Border CC, Kennedy PA, Berger EA. HIV- entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science, 996, 272, 872–876. 34. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor for primary iso- lates of HIV-. Nature, 996, 38, 66–666. 35. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al., HIV- entry into CD4+ cells is medi- ated by the chemokine receptor CC-CKR-5. Nature, 996, 38, 667–673. 36. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier M, Arenzana-Seisdedos F, et al. The CXC chemokine SDF- is the ligand for LESTR/fusin and prevents infection by T-cell- line-adapted HIV-. Nature, 996, 382, 833–835. 37. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, et al. The lymphocyte chemoattractant SDF- is a ligand for LESTR/fusin and blocks HIV- entry. Nature, 996, 382, 829–833. 38. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP- alpha, and MIP- beta as the major HIV-suppressive factors produced by CD8+ T Cells. Science, 995, 270, 8–85. 39. Bieniasz PD, Cullen BR. Chemokine receptors and human immunodeficiency virus infection. Frontiers in Bioscience 998, 3, d44–58. 40. Atchison RE, Gosling J, Monteclaro FS, Franci C, Digilio L, Charo IF, et al. Multiple extracellular elements of CCR5 and HIV- entry: Dissociation from response to chemokines. Sci- ence, 996, 274, 924–926. 4. Bieniasz PD, Fridell RA, Aramori I, Ferguson SSG, Caron MG, Cullen BR. HIV--induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor. EMBO J, 997, 6, 2599–2609. 42. Speck RF, Wehrly K, Platt EJ, Atchison RE, Charo, IF, Kabat D, et al. Selective employment of chemokine receptors as human immunodeficiency virus type  co-receptors deter- mined by individual amino acids within the envelope V3 loop. J Virol, 997, 7, 736–739. 43. Bron R, Klasse PJ, Wilkinson D, Clapham PR, Pelchen- Matthews A, Power C, et al. Promiscuous use of CC and CXC chemokine receptors in cell-to-cell fusion mediated by a human immunodeficiency virus type 2 envelope protein. J Virol, 997, 7, 8405–845. 44. Al-Jabri AA, Mccloskey D, Addawee M, Bottazzo FG, Sachs J, Oxford JS. In Vitro Correlation Between Human Leuko- cyte Antigen Class I and II Phenotype and HIV Infectivity of Activated Peripheral Blood Mononuclear Cell Cultures. AIDS, 998, 2, 27–28. 45. Al-Jabri AA. HLA and in vitro susceptibility to HIV infection. Molecular Immunology, 2002, 38, 959–967. 46. Al-Jabri AA, Bottazo GF, Mccloskey D, Oxford JS. Evidence for Resistance Among PBMCS from Healthy Bangladeshis to Infection by Certain Isolates of HIV- & 2. Abstract P5/, The First European Meeting of Virology, Wurzburg, Germany, September, 995, 0–3. 47. Gartner S, Markovits P, Markovitz D, Kaplan M, Gallo R, H O W D O E S H I V I N F E C T H U M A N C E L L ? 42 Popovic M. The role of mononuclear phagocytes in HTLV- III/LAV infection. Science, 986, 233, 25–29. 48. Cheng-Mayer C, Seto D, Tateno M, Levy JA. Biological fea- tures of HIV that correlate with virulence in the host. Science, 988, 240, 80–82. 49. Fenyo E, Morfeldt-Mason L, Chiodi F, Lind B, VonGegerfelt A, Albert J, Asjo B. Distinctive replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol, 988, 62, 444–449. 50. Schuitemaker H, Kootstra N, de Goede R, de Wolf F, Mie- dema F, Tersmette M. Monocytotropic human immunodefi- ciency virus type  (HIV-) variants detectable at all stages of HIV- infection lack T-cell line tropism and syncytium-induc- ing ability in primary T-cell culture. J Virol, 99, 65, 356-363. 5. Collman R, Balliet JW, Gregory SA, Friedman H, Kolson DL, Nathanson N, Srinivasan A. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type . J Virol, 992, 66, 757–752. 52. Simmons G, Wilkinson D, Reeves JD, Dittmar MT, Beddows S, Weber J, et al. Primary, syncytium-inducing human immu- nodeficiency virus type  isolates are dual-tropic and most can use either Lestr or CCR5 as co-receptors for virus entry. J Virol, 996, 70, 8355–8360. 53. Zhang L, Huang T, He Y, Cao Y, Ho DD. HIV- subtype and second-receptor use. Nature, 996, 383, 768. 54. Arenzanaseisdos F, Virelizier JL, Rousset D, Clark-Lewis I, Loetscher P, Moser B, Baggiolini M. HIV blocked by a chem- okine antagonist. Nature, 996, 383, 400. 55. Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schwartz TW, et al. Potent inhibition of HIV infectivity in macrophages and lymphocytes by a novel CCR-5 antago- nist. Science, 997, 276, 276–279. 56. Kledal TN, Rosenkilde MM, Coulin F, Simmons G, Johnsen AH, Alouani S, et al. A broad spectrum chemokine antagonist encoded by Kaposi’s sarcoma-associated hepesvirus. Science, 997, 277, 656–659. 57. Boschoff C, Endo Y, Collins PD, Takeuchi Y, Reeves JD, Sch- weickart VL, et al. Angiogenic and HIV-inhibitory functions of KSHV encoded chemokines. Science, 997, 278, 290–294. 58. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R., et al. Homozygous defect in HIV- co-receptor accounts for resistance of some multiply-exposed individuals to HIV- infec- tion. Cell, 996, 86, 367–377. 59. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber C-M, et al. Resistance to HIV- infection in caucasian individ- uals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature, 996, 382, 722–725. 60. Cooley LA, Lewin SR. HIV- cell entry and advances in viral entry inhibitor therapy. J Clin Virol, 2003, 26, 2–32. 6. Schols D, Struyf S, Van Damme J, Esté, JA, Henson G, De Clercq E. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med, 997, 86, 383–388. 62. Murakami T, Nakajima T, Koyanagi Y, Tachibana K, Fujii N, Tamamura H, et al. A small molecule CXCR4 inhibitor that blocks T cell- line tropic HIV- infection. J Exp Med, 997, 86, 389–393. 63. Doranz BJ, Grovit-Ferbasi K, Sharron MP, Mao SH, Goetz MB, Daar ES, et al. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV- co-receptor. J Exp Med, 997, 86, 395–400. 64. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in co-receptor use correlates with disease progression in HIV--infected individuals. J Exp Med, 997, 85, 62–628. 65. Connor RI, Mohri H, Cao Y, Ho DD. Increased viral burden and cytopathicity correlate temporally with CD4+ T-lym- phocyte decline and clinical progression in human immuno- deficiency virus type -infected individuals. J Virol, 993, 67, 772–777. 66. Bieniasz PD, Fridell RA, Anthony K, Cullen BR. Murine CXCR-4 is a functional co-receptor for T-cell-tropic and dual- tropic strains of human immunodeficiency virus type . J Virol 997, 7, 7097–700. 67. Tachibana K, Nakajima T, Sato A, Igarashi K, Shida H, Iizasa H, et al. CXCR4/fusin is not a species-specific barrier in murine cells for HIV- entry. J Exp Med, 997, 85, 865–870. 68. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV co-receptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA, 997, 94, 925–930. 69. Malykh A, Reitz MS, Louie A, Hall L, Lori F. Multiple deter- minants for growth of human immunodeficiency virus in monocyte-macrophages. Virology, 994, 206, 646–650. 70. McKnight A, Weiss RA, Chotton C, Takeuchi Y, Hoshino H, Clapham PR. Change in tropism upon immune escape by human immunodeficiency virus. J. Virol, 995, 69, 367–370. 7. Moore JP, Cao Y, Qing L, Sattentau QJ, Pyati J, Koduri R, et al. Primary isolates of human immunodeficiency virus type  are relatively resistant to neutralization by monoclonal anti- bodies to gp20, and their neutralization is not predicted by studies with monomeric gp20. J Virol, 995, 69, 0–09. 72. Biti R, French R, Young J, Bennetts B, Stewart G. HIV- infection in an individual homozygous for the CCR-5 deletion mutant. Nature Med, 997, 3, 252–253. 73. O’Brien TR, Winkler C, Dean M, Nelson JAE, Carrington M, Michael NL, White GC. HIV- infection in a man homozygous for CCR-5 delta32. Lancet, 997, 349, 29. 74. Theodorou I, Meyer l, Magierowska M, Katlana C, Rouzi- oux C. HIV infection in an individual homozygous for CCR-5 delta32. Lancet, 997, 349, 29–220. 75. Balotta C, Bagnarelli P, Violin M, Ridolfo AL, Zho D, Ber- lusconi A, et al. Homozygous delta32 deletion of the CCR-5 chemokine receptor gene in an HIV--infected patient. AIDS, 997, , 67–7. 76. Moore J, Jameson B, Weiss R, Sattentau Q. In Viral Fusion Mechanisms. Ed: J. Bentz Ed. CRC Press, Boca Raton, FL, 993, 233–289. 77. Ferguson SSG, Zhang J, Barak LS, Caron MG. G-protein- coupled receptor kinases and arrestins: regulators of G-pro- tein-coupled receptor sequestration. Biochem Soc Trans 996, 24, 953–959. 78. Gosling J, Monteclaro FS, Atchison RE, Arai H, Tsou C-L, Goldsmith MA, et al. Molecular uncoupling of C-C chemok- AL-JABRI 43 ine receptor 5-induced chemotaxis and signal transd uction from HIV- co-receptor activity. Proc Natl Acad Sci, USA 997, 94, 506–5066. 79. Farzan M, Choe H, Martin KA, Sun Y, Sidelko M, Mackay CR, et al. HIV- entry and macrophage inflammatory pro- tein- beta-mediated signaling are independent functions of the chemokine receptor CCR5. J Biol Chem, 997, 272, 6854– 6857. 80. Aramori I, Zhang J, Ferguson SSG, Bieniasz PD, Cullen BR, Caron M G. Molecular mechanism of desensitization of the chemokine receptor CCR-5: Receptor signalling and internali- zation are dissociable from its role as an HIV- co-receptor. EMBO J, 997, 6, 4606–466. 8. Wigdahl B, Guyton RA, Sarin PS. Human immunodeficiency virus infection of the developing human nervous system. Virology, 987, 59, 440–445. 82. Lifson JD, Reyes GR, McGrath MS, Stein BS, Engleman EG. AIDS retrovirus induced cytopathology: Giant cell formation and involvement of CD4 antigen. Science, 986, 232, 23– 27. 83. Matthews TJ, Weinhold KJ, Lyerly HK, Langlois AJ, Wigzell H, Bolognesi DP. Interaction between the human T-cell lym- photropic virus type IIIB envelope glycoprotein gp20 and the surface antigen CD4: role of carbohydrate in binding and cell fusion. Proc Natl Acad Sci, USA 987, 84, 5424–5428. 84. Andeweg AC, Leeflang P, Osterhaus ADME, Bosch ML. Both the V2 and V3 regions of the human immunodeficiency virus type  surface glycoprotein functionally interact with other envelope regions in syncytium formation. J Virol, 993, 67, 3232–3239. 85. Travis BM, Dykers TI, Hewgill D, Ledbetter J, Tsu TT, Hu SL, et al. Functional roles of the V3 hypervariable region of HIV- gp60 in the processing of gp60 and in the formation of syncytia in CD4+ cells. Virology, 992, 86, 33–37. 86. Trujillo JR, Goletiani NV, Bosch I, Kendrick C, Rogers RA, Trujillo EB, et al. T-tropic sequence of the V3 loop is critical for HIV- infection of CXCR4-positive colonic HT-29 epithe- lial cells. J Acquir Immune Defic Syndr, 2000, 25, –0. 87. Sharer LR. Pathology of HIV- infection of the central nerv- ous system. J Neuropathol Exp Neurol, 992, 5, 3–. 88. Cornelissen M, Mulder-Kampinga G, Veenstra J, Zorgdrager F, Kuiken C, Hartman S, et al. Syncytium-inducing (SI) phe- notype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population. J Virol, 995, 69, 80–88 89. Valentin A, Matsuda S, Asjo B. Characterisation of the in vitro maturation of monocytes and the susceptibility to HIV infection. AIDS Res Hum Retroviruses, 990, 6, 977–978. 90. Wainberg MA, Blain N, Fitz-Gibbon L. Differential suscepti- bility of human lymphocyte cultures to infection by HIV. Clin Exp Immunol, 987, 70, 36–42. 9. Yamada O, Matsumoto T, Sasoaka R, Kurimura T. Variations in growth capacity of HIV in peripheral blood mononuclear cell preparations from different individuals. AIDS, 990, 4, 35–40. 92. Williams LM, Cloyd MW. Polymorphic human gene(s) deter- mines differential susceptibility of CD4 lymphocytes to infec- tion by certain HIV- isolates. Virology, 99, 84, 723–728. 93. Philpott S, Weiser B, Tarwater P, Vermund SH, Kleeberger CA, Gange SJ et al. CC Chemokine Receptor 5 Genotype and Susceptibility to Transmission of Human Immunodeficiency Virus Type  in Women. J Infect Dis, 2003, 87, 569–575. 94. Jennes W, Sawadogo S, Koblavi-Deme S, Vuylsteke B, Mau- rice C, Roels TH et al. Cellular Human Immunodeficiency Virus (HIV)-Protective Factors: A Comparison of HIV- Exposed Seronegative Female Sex Workers and Female Blood Donors in Abidjan, Cote d’Ivoire. J Infect Dis, 2003, 87, 206– 4. 95. Paxton WA, Martin SR, Tse D, O’Brien TR, Skurnick J, Vandevanter NL, et al. Relative resistance to HIV infection of CD4 lymphocytes from persons who remain uninfected despite multiple high risk sexual exposures. Nature Med, 996, 2, 42–47. 96. Connor RI, Paxton WA, Sheridan KE, Koup RA. Macro- phages and CD4+ T lymphocytes from two multiply exposed uninfected individuals resist infection with primary non-syn- cytium inducing isolates of human immunodeficiency virus type . J Virol, 996, 70, 8757–8764. 97. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al. Genetic Restriction of HIV- infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science, 996, 273, 856–862. 98. Meyer L, Magierowska M, Hubert J-B, Rouzioux C, Deveau C, Sanson F, et al. Early protective effect of CCR-5 delta32 het- erozygosity on HIV- disease progression: Relationship with viral load. AIDS, 997, , 73–78. 99. Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of of the Eotaxin receptor CCR-3 by human T helper 2 cells. Science, 997, 277, 2005–2007. 00.He J, Chen Y, Farzan M, Choe H, Ohagen A, Gartner S, et al. CCR3 and CCR5 are co-receptors for HIV- infection of microglia. Nature, 997, 385, 645–649. 0. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV- infection and disease progression. Science, 997, 277, 959–965. 02. Wu BL, Paxton WA, Kassam N, Ruffing N, Rottman JB, Sul- livan N, et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV- in vitro. J Exp Med, 997, 85, 68–69. H O W D O E S H I V I N F E C T H U M A N C E L L ? How does HIV-1 infect a susceptible human cell?Current thinking Ali A. Al-Jabri The human immunodeficiency viruses (HIVs) HIV-1 HIV-2 Subtypes of HIVs Cell tropism in HIVs V3 loop of the glycoprotein (gp) 120 Chemokines are the co-receptors for HIVs entry Role of chemokine co-receptors Co-receptor recognition Cell lines and in-vitro infection with HIVs HIVs affect on receptor usage Glycoprotein-120 co-receptor interactions Inhibition of HIVs entry Cytopathic effects produced by in vitro infection with HIVs Susceptibility of PBMCs to infection with HIVs Resistance to HIV infection Conclusion REFERENCES